title: Hepatitis B reactivation and timing for prophylaxis.
abstract: It is known that immunotherapy and cancer chemotherapy may cause hepatitis B virus (HBV) reactivation in hepatitis B surface antigen carriers and inactive chronic hepatitis B patients. Guidelines recommend antiviral prophylaxis regardless of HBV DNA levels to prevent reactivation. We read from the article written by Liu et al that Lamivudine was given inadequate time for antiviral prophylaxis.
authors.affiliation: Nazan Tuna, Oguz Karabay, Department of Infectious Diseases, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey.
authors.forename: Nazan
authors.initials: N
authors.lastname: Tuna
authors.affiliation: Nazan Tuna, Oguz Karabay, Department of Infectious Diseases, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey.
authors.forename: Oguz
authors.initials: O
authors.lastname: Karabay
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006147:Guanine / Q000031:analogs & derivatives*; D006509:Hepatitis B / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008297:Male; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D006147:Guanine
keywords: Antiviral prophylaxis; Hepatitis B; Hepatitis B reactivation; Immunotherapy; Inadequate time; Lamivudine